Equity

Moderna·Balance Sheet Statement·18 metrics

Breakdown

Metric	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Total liabilities and stockholders' equity	$15.7B	$15.8B	$14.1B	$12.7B	$12B	$12.1B	$12.3B	$11.5B
Total stockholders' equity	$11.7B	$11.9B	$10.9B	$10.1B	$9.4B	$9.3B	$8.7B	$7.4B
Retained earnings	$11.2B	$11.2B	$10B	$9.1B	$8.2B	$8B	$7.2B	$5.9B
Common stock	1.6B	1.6B	0	1.6B	1.6B	1.6B	1.6B	1.6B
Additional paid-in capital	$631M	$751M	$866M	$982M	$1.1B	$1.3B	$1.4B	$1.5B
Share-Based Payment - Unrecognized Cost of Nonvested Awards	$1B	$875M	—	$1.1B	$908M	$770M	—	$978M
Common Stock Shares Issued	384M	385M	386M	387M	389M	391M	394M	397M
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss	$4.8B	$3.6B	$2.6B	$1.4B	$567M	$499M	$283M	$271M
Convertible Preferred Stock Authorized Shares	162M	162M	162M	162M	162M	162M	162M	162M
Accumulated other comprehensive income (loss)	-$71M	$11M	-$10M	$10M	$23M	$27M	$45M	$25M
Investments - Gross Unrealized Losses	$94M	$34M	$28M	$13M	$9M	$5M	$4M	$11M
Common Stock Par Value Per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Preferred Stock Par Value Per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Convertible Preferred Stock Issued Shares	0	0	0	0	0	0	0	0
Convertible Preferred Stock Outstanding Shares	0	0	0	0	0	0	0	0
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$0	$0	$0	$0	$0	$0	$0	$0
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0	$0	$0	$0	$0	$0	$0	$0
Preferred stock	$0	$0	$0	$0	$0	$0	$0	$0